Thermo Fisher Scientific, Inc. ( TMO Quick Quote TMO - Free Report) recently launched the Thermo Scientific iCAP RQplus ICP-MS Analyzer — a new trace elemental analyzer. The analyzer streamlines everyday analyses in environmental, food, pharmaceutical and industrial testing laboratories.
The company also unveils the Thermo Scientific iSC-65 Autosampler to enhance productivity for the Thermo Scientific iCAP Qnova Series ICP-MS analyzer and the Thermo Scientific iCAP PRO Series ICP-OES.
More on the News
The new Thermo Scientific iCAP RQplus ICP-MS Analyzer (left) offers the operational ease and constancy that laboratories need for ongoing daily analysis of trace elements at low concentrations in various sample types.
The Thermo Scientific iSC-65 Autosampler (right) seamlessly incorporates the Thermo Scientific Qtegra ISDS software for maximum control and offers smart automation to enhance ease of use and minimize time per sample with features such as Step Ahead, which enables analysis and wash to be carried out simultaneously.
Benefits of Thermo Scientific iCAP RQplus ICP-MS Analyzer
The Thermo Scientific iCAP RQplus ICP-MS Analyzer instrument delivers accurate results and lessens the potential for quality control failures that lead to rework.
Image Source: Zacks Investment Research
With the new HAWK consumable and maintenance assistant, laboratories also get an advantage from actively monitoring instrument performance and consumables to assure reliable, well-organized and worry-free operation over time.
Industry Prospects Per a report by Grand View Research, the global analytical instrumentation market was valued at USD 53.42 billion in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of 3.53% by 2030. The technological advancements in analytical instrumentation are expected to fuel the industry's growth. Furthermore, growing interest in precision medicine is likely to boost the adoption of analytical instrumentation products. Recent Developments
This month, Thermo Fisher introduced µPAC Neo HPLC Columns for proteomics and biopharmaceutical research laboratories. The addition of a new line of low-flow HPLC columns will improve the separation performance and stability of biologically complex samples.
Last month, Thermo Fisher announced the launch of its Applied Biosystems TrueMark STI Select Panel — a polymerase chain reaction (PCR) research use-only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium in one test and RNase P, included as a human internal control.
Shares of the company have gained 1.5% in the past year against the
industry’s fall of 12.4%. Zacks Rank and Key Picks
Currently, Thermo Fisher carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the overall healthcare sector include
Haemonetics Corporation ( HAE Quick Quote HAE - Free Report) , TerrAscend Corp. and Akerna Corp. ( KERN Quick Quote KERN - Free Report) . Haemonetics and TerrAscend both sport a Zacks Rank #1, while Akerna carries a Zack Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has risen 42.1% in the past year. Earnings Estimates for Haemonetics have increased from $2.87 per share to 2.91 for 2023 and from $3.02 per share to $3.28 for 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the last four quarters, delivering an average surprise of 10.98%. In the last reported quarter, it reported an earnings surprise of 7.59%.
Estimates for TerrAscend in 2023 have remained constant at a loss of 10 cents per share in the past 30 days. Shares of TerrAscend have declined 70.6% in the past year.
TerrAscend’s earnings beat estimates in one of the last three quarters and missed the mark in the other two, the average negative surprise being 136.11%. In the last reported quarter, TRSSF delivered an earnings surprise of 216.67%.
Akerna’s stock declined 95.7% in the past year. Its estimates for 2023 have remained constant at a loss of $1.91 per share over the past 30 days.
Akerna missed earnings estimates in each of the last four quarters, delivering a negative earnings surprise of 15.49%, on average. In the last reported quarter, KERN delivered a negative earnings surprise of 13.33%.